
Get exclusive money-saving offers and guides
Straight to your inbox
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Exopharm Limited is a biotechnology business based in Australia. Exopharm shares (EX1) are listed on the Australian Securities Exchange (ASX) and all prices are listed in Australian Dollars. Exopharm has a trailing 12-month revenue of around $2.7 million.
Our top pick for
US stocks
Our top pick for
Cheap broker fees
Our top pick for
Long-term investing
52-week range | $0.145 - $0.96 |
---|---|
50-day moving average | $0.684 |
200-day moving average | $0.4295 |
Target price | N/A |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-0.04 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Revenue TTM | $2.7 million |
---|---|
Gross profit TTM | $-314,976 |
Return on assets TTM | -55.88% |
Return on equity TTM | -104.15% |
Profit margin | -198.04% |
Book value | 0.053 |
Market capitalisation | $103.9 million |
TTM: trailing 12 months
We're not expecting Exopharm to pay a dividend over the next 12 months.
Over the last 12 months, Exopharm 's shares have ranged in value from as little as $0.145 up to $0.96. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Exopharm 's is 0.9649. This would suggest that Exopharm 's shares are less volatile than average (for this exchange).
Exopharm Limited, a biopharmaceutical company, focuses on developing and commercializing human therapeutics using extracellular vesicles (EVs) as medicines in Australia. The company is developing Naïve EVs as regenerative medicines, including Plexaris for wound healing; and Cevaris used in inflammatory, immunomodulatory, and tissue remodeling activities. Its Engineered EVs products comprise Fortrexo CoV, an engineered EV product that reduce the duration and severity of SARS-CoV-2 infection in the early phase of a patient's exposure to COVID-19; and Plexodox, a platelet derived EV loaded with the approved anti-cancer drug doxorubicin as a novel and improved anticancer drug. The company was founded in 2013 and is headquartered in Melbourne, Australia.
You can now invest as little as 1 cent into Australian, NZ and US shares. Here's why that's a game changer.
Everything we know about the Didi Chuxing IPO, plus information on how to buy in.
Robinhood is set to go public as soon as June. Here's what you need to do to buy in from Australia.
We explain everything you need to make your own retro arcade machine, built around the super-flexible Raspberry Pi.
Beat the banks, find the best exchange rates and avoid fees when you send money abroad from Australia.
All the key info you need to know to sell shares you inherited or received as a gift.
Steps to owning and managing Roblox shares.
Steps to owning and managing Zebit shares.